DB22691InvestigationalSmall molecule
AC-003 is a selective, oral small-molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1). By inhibiting RIPK1 kinase activity, AC-003 thereby inhibits RIPK1-mediated cell death and inflammation. It is being investigated... It is being investigated for the treatment of acute graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF).
- Also known as
- Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)- imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate · Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)-imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate
- Code names
- AC-003
What you can answer from here — as of September 12, 2026
Which companies are running trials of AC-003, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account